doxazosin and valsartan

doxazosin has been researched along with valsartan in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (55.56)29.6817
2010's3 (33.33)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW1
Acikel, C; Caglar, K; Celik, T; Eyileten, T; Oguz, Y; Sonmez, A; Vural, A; Yavuz, I; Yenicesu, M; Yilmaz, MI1
Boj, M; Camprubí, M; Hernandez-Flix, S; Solà, R1
Gandhi, HP; Giridhar, R; Naik, PP; Yadav, MR1

Reviews

1 review(s) available for doxazosin and valsartan

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for doxazosin and valsartan

ArticleYear
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
    Nephrology (Carlton, Vic.), 2007, Volume: 12, Issue:2

    Topics: Adiponectin; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Body Mass Index; Calcium Channel Blockers; Doxazosin; Female; Humans; Hypertension; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Metoprolol; Middle Aged; Predictive Value of Tests; Prospective Studies; Ramipril; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2007

Other Studies

7 other study(ies) available for doxazosin and valsartan

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
    Journal of biomedical science, 2005, Volume: 12, Issue:2

    Topics: Acetylcysteine; Animals; Antihypertensive Agents; Aorta; Arteries; Blotting, Western; Body Weight; Carbazoles; Carvedilol; Down-Regulation; Doxazosin; Echocardiography; Hemodynamics; Hypertrophy; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Myocardium; Nerve Growth Factor; Organ Size; Pressure; Propanolamines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Transcription Factors; Valine; Valsartan; Vascular Endothelial Growth Factor A; Vasodilator Agents

2005
Silica in oral drugs as a possible sarcoidosis-inducing antigen.
    Lancet (London, England), 2009, Jun-06, Volume: 373, Issue:9679

    Topics: Administration, Oral; Antigens; Antihypertensive Agents; Bisoprolol; Causality; Chemistry, Pharmaceutical; Doxazosin; Humans; Hypertension; Male; Middle Aged; Pharmaceutical Vehicles; Sarcoidosis, Pulmonary; Silicon Dioxide; Tetrazoles; Valine; Valsartan

2009
Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.
    Pharmaceutical biology, 2012, Volume: 50, Issue:4

    Topics: Adrenergic alpha-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Dose-Response Relationship, Drug; Doxazosin; Imidazoles; In Vitro Techniques; Losartan; Male; Molecular Structure; Prazosin; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan; Vasodilation; Vasodilator Agents

2012
chemdatabank.com